

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Continuation Patent
Application of
Kozlov et al

Atty. Ref.: **1331-338**

Serial No. **To be Assigned**

Group:

Filed: **April 23, 2001**

Examiner:

For: **Inhibitor of Stem Cell Proliferation and Uses Thereof**

* * * * *

April 23, 2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

PRELIMINARY AMENDMENT

Preliminarily amend the above-identified application as follows:

IN THE SPECIFICATION

Amend the specification as follows:

Page 1, delete the first paragraph, and insert the following therefor:

--This application is a continuation of application Serial No. 08/477,668, filed June 7, 1995, now pending, which is a divisional of application Serial No. 08/316,424 filed September 30, 1994, which is a continuation-in-part application of PCT/US94/03349 filed March 29, 1994, which in turn is a continuation-in-part application of U.S. Serial No. 08/040,942 filed March 31, 1993, the entire contents of each of which are hereby incorporated by reference.--

Page 12, delete paragraph 3, and insert the following therefor:

--Fig. 16 shows hemoglobin sequences: Fig. 16A shows the cDNA (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of human alpha hemoglobin and Fig. 16B shows the cDNA (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences of human beta hemoglobin. Numbering is according to the amino acid. Fig. 16C shows an amino acid sequence comparison of the alpha and beta chains of human (SEQ ID NO:2 and SEQ ID NO:4), murine (SEQ ID NO:5 and SEQ ID NO:6) and porcine (SEQ ID NO:7 and SEQ ID NO:8) hemoglobins.--

Page 41, delete the penultimate paragraph, and insert the following therefor:

--The pellet is dissolved in HPLC eluent buffer A containing 5% acetonitrile (MeCN) and 0.1% trifluoroacetic acid (TFA) to final protein concentration 8-10 mg/ml. This solution (0.5-0.6 ml) is loaded onto 250 x 4.6 mm HPLC column packed with Porisil ODS-300 (10 mcm) and equilibrated with the same buffer A.--

Page 44, delete the third paragraph, and insert the following therefor:

--VHLSAEEKEAVLGLWGKVNDEV ... (SEQ ID NO:9).--

Page 44, delete the seventh paragraph, and insert the following therefor:

--VLSAADKANVKAAWGVGGQ....(SEQ ID NO:10).--

Page 44, delete the eighth paragraph, and insert the following therefor:

--The 30 kD band was subjected to limited proteolytic digest and the following internal sequence was obtained: * * FPHFNLSHGSDQVK....(SEQ ID NO:11).--

Insert the attached Sequence Listing after the claims pages.

IN THE CLAIMS

Amend the claims as follows:

Cancel claims 1-26, without prejudice.

Add the following claims:

--27. (new) A pharmaceutical composition consisting essentially of the alpha globin chain of hemoglobin in a pharmaceutically acceptable carrier, wherein the composition is suitable for subcutaneous administration.

28. (new) A pharmaceutical composition consisting essentially of the beta globin chain of hemoglobin in a pharmaceutically acceptable carrier, wherein the composition is suitable for subcutaneous administration.

29. (new) A pharmaceutical composition consisting of the alpha globin chain of hemoglobin and the beta globin chain of hemoglobin in a pharmaceutically acceptable carrier, wherein the composition is suitable for subcutaneous administration.

30. (new) A pharmaceutical composition as in claim 27 wherein said alpha globin chain is present in an amount of 0.1 mg to 6 g.

31. (new) A pharmaceutical composition as in claim 28 wherein said beta globin chain is present in an amount of 0.1 mg to 6 g.

32. (new) A pharmaceutical composition as in claim 29 wherein said beta globin chain and said alpha globin chain are each present in an amount of 0.1 mg to 6 g.--

REMARKS

The claims have been amended to pursue subject matter which the Examiner refused to enter in the parent Application No. 08/477,668. See, the Advisory Action of March 23, 2001.

The specification has been amended to include amendments made in the parent application.

The attached paper copy of the Sequence Listing is the same as the computer-readable copy of the Sequence Listing filed in the parent Application No. 08/477,668. The Office is requested to use the computer-readable copy of the Sequence Listing from the parent Application No. 08/477,668. No new matter has been added. A separate Letter to this affect is attached.

Consideration of the attached Information Disclosure Statement and return of an initialed copy of the PTO-1449 Form listing the references cited in the parent Application No. 08/477,668, are requested.


An early and favorable Action on the merits is requested.

Kozlov et al
Serial No. To be Assigned

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



B. J. Sadoff
Reg. No. 36,663

BJS:eaw

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

MARKED UP SPECIFICATION AND CLAIMS

Page 1, delete the first paragraph, and insert the following therefor:

--This application is a continuation of application Serial No. 08/477,668, filed June 7, 1995, now pending, which is a divisional of application Serial No. 08/316,424 filed September 30, 1994, which is a continuation-in-part application of PCT/US94/03349 filed March 29, 1994, which in turn is a continuation-in-part application of [US Ser. No. 08/040924] U.S. Serial No. 08/040,942 filed March 31, 1993, [both of which] the entire contents of each of which are hereby incorporated by reference.--

Page 12, delete paragraph 3, and insert the following therefor:

--Fig. 16 shows hemoglobin sequences: Fig. 16A shows the cDNA (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of human alpha hemoglobin and Fig. 16B shows the cDNA (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences of human beta hemoglobin. Numbering is according to the amino acid. Fig. 16C shows an amino acid sequence comparison of the alpha and beta chains of human (SEQ ID NO:2 and SEQ ID NO:4), murine (SEQ ID NO:5 and SEQ ID NO:6) and porcine (SEQ ID NO:7 and SEQ ID NO:8) hemoglobins.--

Page 41, delete the penultimate paragraph, and insert the following therefor:

--The pellet is dissolved in HPLC eluent buffer A containing 5% acetonitrile (MeCN) and 0.1% triflouroacetic acid (TFA) to final protein concentration 8-10 mg/ml.

This solution (0.5-0.6 ml) is loaded onto 250 x 4.6 mm HPLC column packed with [Polisil] Porasil ODS-300 (10 mcm) and equilibrated with the same buffer A.--

Page 44, delete the third paragraph, and insert the following therefor:

--VHLSAEEKEAVLGLWGKVNDEV ...(SEQ ID NO:9).--

Page 44, delete the seventh paragraph, and insert the following therefor:

--VLSAADKANVKAAWGKVGGQ.....(SEQ ID NO:10).--

Page 44, delete the eighth paragraph, and insert the following therefor:

--The 30 kD band was subjected to limited proteolytic digest and the following

internal sequence was obtained: * * FPHFNLSHGSDQVK....(SEQ ID NO:11).--